Techknow Webinar Series Presentation
Paradigm's MD, Paul Rennie, recently participated in the TechKnow Webinar Series, to provide an overview of the enormous addressable market for knee OA and the unmet need that remains for those suffering. Paul discussed the current Phase 3 clinical trial and upcoming events for investors.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Paradigm Biopharmaceuticals. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Paradigm Biopharmaceuticals a question about this update.